Key Points Happily for investors, it flagged the biotech's shares as a buy. Goldman believes they have nearly 40% upside. 10 stocks we like better than Iovance Biotherapeutics › A new, bullish analyst take on Iovance Biotherapeutics (NASDAQ: IOVA) put the company's shares in the win column on Thursday. That analysis was published by an always-influential investment bank, and it improved sentiment on Iovance sufficiently to send the shares to an almost 6% gain. It's golden with Goldman That morning Goldman Sachs , in the person of pundit Andrea Newkirk, resumed coverage of Iovance, a biotech that concentrates on developing cancer therapies. She rated Iovance's equity a buy at a price target of $15 per share. Missed Nvidia in 2009?
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.